PE20030417A1 - Derivados de urea como antagonistas del receptor vainilloide - Google Patents

Derivados de urea como antagonistas del receptor vainilloide

Info

Publication number
PE20030417A1
PE20030417A1 PE2002000895A PE2002000895A PE20030417A1 PE 20030417 A1 PE20030417 A1 PE 20030417A1 PE 2002000895 A PE2002000895 A PE 2002000895A PE 2002000895 A PE2002000895 A PE 2002000895A PE 20030417 A1 PE20030417 A1 PE 20030417A1
Authority
PE
Peru
Prior art keywords
urea
alkyl
pyridyl
trifluoromethyl
aryl
Prior art date
Application number
PE2002000895A
Other languages
English (en)
Inventor
Harshad Kantilal Rami
Mervyn Thompson
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20030417A1 publication Critical patent/PE20030417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS DE UREA DE FORMULA I DONDE P Y P' SON ARILO, HETEROARILO; R1 Y R2 SON H, HALOGENO, ALQUILO, ALCOXI, CICLOALQUILO, ARALQUILO, ARALCOXI, CICLOALQUILALQUILO, CN, NO2, OH, OCF3, CF3, ENTRE OTROS; R4 Y R5 SON H, ALQUILO O JUNTOS FORMAN UN ANILLO AZACICLOALCANO C3-C6, (2-OXO)AZACICLOALCANO C3-C6, CADENA POLIMETILENO C5-C8; Z ES O, S, NR7; R6 ES ALQUILO, ARILO, R7 ES H, ALQUILO, ARILO; m ES 1-2; n ES 0-3; p Y q SON 0-4; r ES 1-3; s ES 0-2; x ES 0-6; EXCEPTO LOS COMPUESTOS 1-(1-FENIL-3-PIRROLIDINIL)-3-FENIL-UREA; 1-(1-FENIL-3-PIRROLIDINIL)-3-(4-METOXIFENIL)-UREA, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(2-BROMOFENIL)-N'-[(®-1-(5-TRIFLUOROMETIL-2-PIRIDIL)PIRROLIDIN-3-IL)]UREA; N-(ISOQUINOL-5-IL)-N'-[(®-1-(5-TRIFLUOROMETIL-2-PIRIDIL)-PIRROLIDIN-3-IL)]UREA; (+/-)-N-(ISOQUINOL-5-IL)-N'-[(1-(5-TRIFLUOROMETIL-2-PIRIDIL)-PIPERIDIN-3-IL)]UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR VAINILLOIDE Y PUEDEN SER UTILES PARA EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICO, POST OPERATORIO, ARTRITICO POST REUMATOIDE, OSTEOARTRITICO, MIGRANAS, NEUROPATIAS, SINDROME DEL CANAL CARPIANO, NEUROPATIA DIABETICA
PE2002000895A 2001-09-13 2002-09-11 Derivados de urea como antagonistas del receptor vainilloide PE20030417A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds

Publications (1)

Publication Number Publication Date
PE20030417A1 true PE20030417A1 (es) 2003-08-06

Family

ID=27447989

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000895A PE20030417A1 (es) 2001-09-13 2002-09-11 Derivados de urea como antagonistas del receptor vainilloide

Country Status (32)

Country Link
US (1) US8063078B2 (es)
EP (3) EP1425277B8 (es)
JP (2) JP4463552B2 (es)
KR (3) KR101063679B1 (es)
CN (1) CN1247568C (es)
AP (1) AP1818A (es)
AR (1) AR038786A1 (es)
AT (1) ATE420083T1 (es)
AU (1) AU2002329397B2 (es)
BR (1) BR0212468A (es)
CA (1) CA2458632C (es)
CY (1) CY1109449T1 (es)
DE (1) DE60230773D1 (es)
DK (1) DK1425277T3 (es)
EA (1) EA007731B1 (es)
ES (1) ES2316607T3 (es)
HK (1) HK1066534A1 (es)
HU (1) HUP0401923A3 (es)
IL (2) IL160755A0 (es)
MA (1) MA26216A1 (es)
MX (1) MXPA04002379A (es)
MY (1) MY138086A (es)
NO (3) NO327009B1 (es)
NZ (1) NZ531137A (es)
OA (1) OA12659A (es)
PE (1) PE20030417A1 (es)
PL (1) PL213639B1 (es)
PT (1) PT1425277E (es)
SI (1) SI1425277T1 (es)
TW (1) TWI283665B (es)
UY (1) UY27446A1 (es)
WO (1) WO2003022809A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030417A1 (es) 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004052846A1 (en) 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2004078749A1 (en) * 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2004078744A2 (en) * 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
CA2540647C (en) 2003-10-01 2012-07-10 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
WO2005035471A1 (ja) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. エーテル誘導体
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
CA2545109A1 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
EP1771162B1 (en) 2004-07-19 2013-06-05 Xenia Pharma Capsaicin inhibitors for the treatment of obesity-related disorders
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
JP5254228B2 (ja) * 2006-07-27 2013-08-07 株式會社アモーレパシフィック バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US7767705B2 (en) 2006-08-25 2010-08-03 Abbott Laboratories Compounds that inhibit TRPV1 and uses thereof
EP2450346A1 (en) 2006-12-20 2012-05-09 Abbott Laboratories Antagonists of the TRPV1 receptor and uses thereof
JP2011515414A (ja) 2008-03-20 2011-05-19 アボット・ラボラトリーズ Ｔｒｐｖ１アンタゴニストである中枢神経系薬剤を作製する方法
CA2719515C (en) 2008-04-18 2013-11-05 Daewoong Pharmaceutical Co., Ltd. A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
EP2484664B1 (en) * 2008-05-07 2013-09-04 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
JP2012501315A (ja) * 2008-09-02 2012-01-19 グラクソ グループ リミテッド 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
JP2014510768A (ja) 2011-04-11 2014-05-01 グラクソ グループ リミテッド Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
DE68918991T2 (de) 1988-06-17 1995-04-27 Procter & Gamble Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
AU9079491A (en) 1990-11-27 1992-06-25 Procter & Gamble Company, The Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
CA2294042A1 (en) * 1997-06-26 1999-01-07 David Kent Herron Antithrombotic agents
CA2294240A1 (en) * 1997-06-26 1999-01-07 Trelia Joyce Craft Antithrombotic agents
JP2000080085A (ja) 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
ES2253208T3 (es) 1999-02-22 2006-06-01 Pacific Corporation Analogos de vaniloide que contienen farmacoforos de resiniferatoxina como ponentes agonistas del receptor de vaniloide y analgesicos, composiciones y utilizaciones de los mismos.
KR100709497B1 (ko) 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
EP1220836A2 (en) * 1999-10-15 2002-07-10 Bristol-Myers Squibb Pharma Company Benzylcycloalkyl amines as modulators of chemokine receptor activity
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
EP1303483B1 (en) 2000-08-21 2008-04-23 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
US20030203944A1 (en) 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
DE60120421T2 (de) 2000-08-21 2006-12-28 Pacific Corp. Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) * 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
EP1534681A1 (en) * 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
JP2007533673A (ja) 2004-04-20 2007-11-22 バイエル・ヘルスケア・アクチェンゲゼルシャフト バニロイド受容体（ｖｒ１）のアンタゴニストとしての尿素誘導体

Also Published As

Publication number Publication date
KR20100082390A (ko) 2010-07-16
EA200400432A1 (ru) 2004-12-30
EP2298757A2 (en) 2011-03-23
ATE420083T1 (de) 2009-01-15
NO20085078L (no) 2004-06-04
CY1109449T1 (el) 2014-08-13
EP2036902A3 (en) 2009-05-06
CA2458632C (en) 2011-08-23
BR0212468A (pt) 2004-10-19
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
PL369026A1 (en) 2005-04-18
TWI283665B (en) 2007-07-11
US8063078B2 (en) 2011-11-22
KR101063679B1 (ko) 2011-09-07
IL160755A0 (en) 2004-08-31
JP4463552B2 (ja) 2010-05-19
EP2036902A2 (en) 2009-03-18
SI1425277T1 (sl) 2009-04-30
DE60230773D1 (de) 2009-02-26
KR20090026369A (ko) 2009-03-12
WO2003022809A3 (en) 2003-07-17
NO20085077L (no) 2004-06-04
PL213639B1 (pl) 2013-04-30
HK1066534A1 (en) 2005-03-24
AP2004002982A0 (en) 2004-03-31
WO2003022809A2 (en) 2003-03-20
UY27446A1 (es) 2003-04-30
MA26216A1 (fr) 2004-07-01
JP2005504074A (ja) 2005-02-10
AU2002329397B2 (en) 2006-04-27
EP2298757A3 (en) 2011-12-28
CN1247568C (zh) 2006-03-29
CN1553905A (zh) 2004-12-08
HUP0401923A3 (en) 2012-09-28
MXPA04002379A (es) 2004-05-31
CA2458632A1 (en) 2003-03-20
EP1425277A2 (en) 2004-06-09
EA007731B1 (ru) 2006-12-29
DK1425277T3 (da) 2009-03-16
NO20041003L (no) 2004-06-04
AP1818A (en) 2008-01-07
AR038786A1 (es) 2005-01-26
IL160755A (en) 2009-09-01
NZ531137A (en) 2006-08-31
KR20040041610A (ko) 2004-05-17
EP1425277B8 (en) 2009-04-01
ES2316607T3 (es) 2009-04-16
KR100955967B1 (ko) 2010-05-04
MY138086A (en) 2009-04-30
EP1425277B1 (en) 2009-01-07
NO327009B1 (no) 2009-04-06
OA12659A (en) 2006-06-19
HUP0401923A2 (hu) 2005-01-28
JP2010100632A (ja) 2010-05-06

Similar Documents

Publication Publication Date Title
PE20030417A1 (es) Derivados de urea como antagonistas del receptor vainilloide
CO5280079A1 (es) Nuevos compuestos
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
PE20050896A1 (es) Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos
PE20020354A1 (es) Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
ATE449083T1 (de) Chinazolin-derivate und ihre verwendung als arzneimittel
AR027402A1 (es) Derivados de pirimidina.
RU2004120553A (ru) Производные никотинамида, полезные в качестве р38-ингибиторов
AR042024A1 (es) Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona
PE20220341A1 (es) Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20030593A1 (es) DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
HUP0400326A2 (hu) Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
PE20070113A1 (es) Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb
NO20063132L (no) Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR062299A1 (es) Derivados de bencimidazol
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
AR049995A1 (es) Un procedimiento de preparacion de derivados n-piperidino-1,5-difenilpirazol-3-carboxamida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed